Fasoracetam, formerly known as NS-105; NFC-1; LAM-105, is a GABA receptor modulator potentially for the treatment of attention deficit hyperactivity disorder. It is a nootropic, and has been in a clinical trial for attention deficit hyperactivity disorder. In in vitro studies on mouse neurons, fasoracetam modulated mGluR II/III activity. In studies in rats, it blocked memory disruptions caused by baclofen, a GABAB agonist and upregulated production of GABAB receptors after repeat dosing. References: Chugh G, Asghar M, Patki G, Bohat R, Jafri F, Allam F, Dao AT, Mowrey C, Alkadhi K, Salim S. A high-salt diet further impairs age-associated declines in cognitive, behavioral, and cardiovascular functions in male Fischer brown Norway rats. J Nutr. 2013 Sep;143(9):1406-13. doi: 10.3945/jn.113.177980. Epub 2013 Jul 17. PubMed PMID: 23864508; PubMed Central PMCID: PMC3743272.

纯度：≥98%

CAS：110958-19-5